Neuroectodermal Tumors clinical trials at UCSF
1 research study open to eligible people
Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
open to eligible people ages 1 year and up
The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma
San Francisco, California and other locations
Our lead scientists for Neuroectodermal Tumors research studies include Kieuhoa Vo.